Keros Therapeutics Inc. Common Stock (KROS)

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

92

Website

www.kerostx.com/

Fundamentals

1-day range

$10.59$11.16

Market cap

$211.16M

P/E (trailing)

—

P/E (forward)

-1.67

EPS (trailing)

$-3.70

Dividend yield

—

Beta

1.14

Avg. volume

245.5K

Forecasts

6 analyst ratings

Keros Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KROS

  Keros Therapeutics Inc. Common Stock

  $11.05

  ▼ 1.60%
  Market cap $211.16MP/E —
  $9.69$22.55
• MSLE

  Satellos Bioscience Inc. Common Stock

  $8.92

  ▼ 7.23%
  Market cap $209.77MP/E —
  $7.08$18.98
• RNA

  Atrium Therapeutics Inc. Common Stock

  $13.64

  ▼ 2.43%
  Market cap $207.15MP/E —
  $11.13$16.77
• NERV

  Minerva Neurosciences Inc Common Stock

  $4.85

  ▼ 5.56%
  Market cap $206.85MP/E —
  $1.93$12.46
• SIGA

  SIGA Technologies Inc. Common Stock

  $3.07

  ▲ 0.33%
  Market cap $223.78MP/E —
• NBP

  NovaBridge Biosciences American Depositary Shares

  $1.85

  ▼ 2.38%
  Market cap $196.15MP/E —
  $1.46$6.79
• ACIU

  AC Immune SA Common Stock

  $2.67

  ▼ 1.48%
  Market cap $236.11MP/E —

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
  Benzinga · 8/4/2026
• Keros Therapeutics Reports Second Quarter 2026 Financial Results
  Yahoo · 8/3/2026
• Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
  Benzinga · 8/3/2026

• Jean Jacques Bienaime · July 15, 2026 · Buy

  1.0K @ $10.61
• Anne Prener · July 1, 2026 · Grant

  14.9K
• Anne Prener · July 1, 2026 · Grant

  13.8K
• Jean Jacques Bienaime · June 15, 2026 · Buy

  1.0K @ $10.19
• Charles W. Newton · June 11, 2026 · Sale

  550 @ $10.04
• Julius Knowles · June 4, 2026 · Sale

  2.6K @ $10.73
• Nima Farzan · June 4, 2026 · Sale

  2.6K @ $10.73
• Alpna Seth · June 4, 2026 · Sale

  2.6K @ $10.72
• Julius Knowles · June 3, 2026 · Grant

  7.4K
• Julius Knowles · June 3, 2026 · Grant

  7.1K
• Nima Farzan · June 3, 2026 · Grant

  7.4K
• Nima Farzan · June 3, 2026 · Grant

  7.1K
• Alpna Seth · June 3, 2026 · Grant

  7.4K
• Alpna Seth · June 3, 2026 · Grant

  7.1K
• Mary Ann Gray · June 3, 2026 · Grant

  7.4K

Institutional Ownership

March 31, 2026

Total shares held

18.03M

Total value held

$195.30M

Institutional holders

146